This reveals the unique prognostic value of MAGE-D2 for HCC and indicates that HCC patients with increased expression of MAGE-D2 must be categorized into a high-risk group with an adverse prognosis even during the early stage of HCC. This evidence concerns the gene MAGED2 and hepatocellular carcinoma.